Sugi Predict

Sugi Predict / Compounds / SCHEMBL426773

SCHEMBL426773

SCHEMBL426773

COc1cc(Br)ccc1CC(=O)O

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 1/20 0.54
▸ NR1H4 Q96RI1 1/20 0.49
▸ ALDH1A1 P00352 5/20 0.47
▸ KDM4E B2RXH2 4/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ PYCR1 P32322 1/20 0.47
▸ GAA P10253 3/20 0.46
▸ TDP1 Q9NUW8 2/20 0.46
▸ TSHR P16473 1/20 0.46
▸ NFKB1 P19838 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ MAPT P10636 1/20 0.45
▸ KDM4C Q9H3R0 1/20 0.44
▸ PTGDR2 Q9Y5Y4 2/20 0.44
▸ CYP3A4 P08684 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29383625 1.00 HSD17B10 (0.54) HSD17B10NR1H4ALDH1A1KDM4ESMN1; SMN2
SCHEMBL1240204 0.86 CYP3A4 (0.61) ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL154368 0.86 HSD17B10 (0.68) HSD17B10ALDH1A1KDM4ESMN1; SMN2MEN1
SCHEMBL29835995 0.85 KDM4E (0.47) HSD17B10ALDH1A1KDM4ESMN1; SMN2MEN1
SCHEMBL22918243 0.85 KDM4E (0.47) HSD17B10ALDH1A1KDM4ESMN1; SMN2MEN1
SCHEMBL29002583 0.85 PYCR1 (0.46) ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL5107368 0.85 HSD17B10 (0.54) HSD17B10KDM4EMEN1KMT2ATSHR
SCHEMBL20562481 0.83 POLB (0.53) ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL29844957 0.83 THRB (0.47) HSD17B10SMN1; SMN2KMT2ATSHRPTGDR2
SCHEMBL16898291 0.83 THRB (0.47) HSD17B10SMN1; SMN2KMT2ATSHRPTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260144743-A1 COMPOUNDS TMEM16A LIMITED (GB) 2026-05-28 — — US disclosed
EP-4699655-A2 COMPOUNDS TMEM16A LIMITED (GB) 2026-02-25 — — EP disclosed
US-20260034140-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA LTD (GB) 2026-02-05 — — US disclosed
US-12503452-B2 Antimicrobial compounds and methods CURZA GLOBAL, LLC (US) 2025-12-23 — — US disclosed
US-12497382-B2 GLP-1R modulating compounds GILEAD SCIENCES, INC. (US) 2025-12-16 — — US disclosed
US-12453734-B2 Modulators of rho-associated protein kinase REDX PHARMA LIMITED (GB) 2025-10-28 — — US disclosed
US-12377105-B2 Compounds TMEM16A LIMITED (GB) 2025-08-05 — — US disclosed
US-20250213700-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR CELL-SPECIFIC PHARMACOLOGY FOX CHASE CHEMICAL DIVERSITY CENTER, INC. 2025-07-03 — — US disclosed
WO-2025124429-A1 AROMATIC AMINE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF 北京康辰药业股份有限公司 2025-06-19 — — WO disclosed
US-20240216386-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA LIMITED (GB) 2024-07-04 — — US disclosed
EP-2081890-A1 ARYLSULFONYL PYRROLIDINES AS 5-HT6 INHIBITORS F. Hoffmann-Roche AG (CH) 2009-07-29 — — EP disclosed
US-20080167361-A1 Arylsulfonyl pyrrolidines as 5-HT6 inhibitors ROCHE PALO ALTO LLC 2008-07-10 — — US disclosed
US-20080167361-A1 Arylsulfonyl pyrrolidines as 5-HT6 inhibitors ROCHE PALO ALTO LLC 2008-07-10 — — US disclosed
US-20080167361-A1 Arylsulfonyl pyrrolidines as 5-HT6 inhibitors ROCHE PALO ALTO LLC 2008-07-10 — — US disclosed
WO-2008055847-A1 ARYLSULFONYL PYRROLIDINES AS 5-HT6 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2008-05-15 — — WO disclosed
WO-2008055847-A1 ARYLSULFONYL PYRROLIDINES AS 5-HT6 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2008-05-15 — — WO disclosed
EP-1077701-A4 ANTI-VIRAL COMPOUNDS LILLY CO ELI (US) 2002-03-20 — — EP disclosed
CN-1292697-A Anti-viral compound LILLY CO ELI (US) 2001-04-25 — — CN disclosed
EP-1077701-A1 ANTI-VIRAL COMPOUNDS ELI LILLY AND COMPANY (US) 2001-02-28 — — EP disclosed
WO-1999059587-A1 ANTI-VIRAL COMPOUNDS ELI LILLY AND COMPANY (US) 1999-11-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260144743-A1 COMPOUNDS CACNA1E, TMEM109, CACNA1C HSD17B10 868/4885NR1H4 1840/4885ALDH1A1 1592/4885
US-20260034140-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE ROCK1, ROCK2, RHOA HSD17B10 4620/4885NR1H4 3518/4885ALDH1A1 4825/4885
US-12453734-B2 Modulators of rho-associated protein kinase ROCK2, ROCK1, RHOA HSD17B10 3389/4885NR1H4 1402/4885ALDH1A1 4441/4885
US-20240216386-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE ROCK2, ROCK1, RHOA HSD17B10 3389/4885NR1H4 1402/4885ALDH1A1 4441/4885
US-20080167361-A1 Arylsulfonyl pyrrolidines as 5-HT6 inhibitors HTR6, HTR1B, HTR1F HSD17B10 3394/4885NR1H4 1581/4885ALDH1A1 619/4885
US-20250213700-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR CELL-SPECIFIC PHARMACOLOGY DDT, ABCG2, CES2 HSD17B10 130/4885NR1H4 530/4885ALDH1A1 179/4885
US-12497382-B2 GLP-1R modulating compounds GLP1R, GIPR, GPR119 HSD17B10 1642/4885NR1H4 432/4885ALDH1A1 3556/4885
US-12377105-B2 Compounds CACNA1E, TMEM109, CACNA1A HSD17B10 2273/4885NR1H4 2976/4885ALDH1A1 2218/4885
US-12503452-B2 Antimicrobial compounds and methods MPO, NISCH, RPN2 HSD17B10 3006/4885NR1H4 3321/4885ALDH1A1 3752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.